IONICSCALE LLC

ATLANTA, GA · Medtech · Private

Chip-scale ion trap mass analyzer for compact, portable mass spectrometers

ionicscale.com →
Grants
$1.4M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$166K
1 award · Homeland Security
#474 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I:Low cost, portable mass spectrometers based on a chip-scale ion trap mass analyzer$256,000
Federal grantDepartment of Agriculture · With The Growing Demand For Effective, Yet Socially And Environmentally Conscious Solutions To Our Fundamental Agricultural Supply Chains, The Need For Widely Deployable Sensing Instruments To Detect And Monitor Chemical Signatures Of Contamination, Infestation, Or Other Potential Issues Is Critically Needed. Ionicscale Llc Is Developing Low-cost, Compact Mass Spectrometry-based Chemical Sensors That Can Be Utilized For This Purpose, Among Many Others.this Phase I Project Will Enable Substantial$175,000
Federal grantNational Science Foundation · Phase II · SBIR Phase II: An ultra-compact, remotely programmable chemical analyzer utilizing a novel ion trap mass spectrometer$1,000,000
Federal contractDepartment of Homeland Security · New Contract For SBIR Phase I Topic 1: DHS241-001 Agnostic Detection Of Synthetic Opioids And Other Illicit Drugs.$166,089
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
471Assurex Health$171K—
472Gold Standard Diagnostics Corp.$167K$2.5M
473CMP Scientific Corp$167K$300K
474IONICSCALE LLC$166K—
475GPB Scientific, Inc.$164K$41M
476iRhythm Technologies, Inc.$163K$59M
477Coalesenz Inc.$163K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.